Clay Siegall, M.D., Ph.D., is the founder of Seattle Genetics. This specific biotech company produces one of the most successful cancer-fighting drugs of all-time, and it has helped to generate over $300 million in revenue. This drug is known as ADCETRIS, and it is a targeted-cancer medication. Dr. Siegall has used his years of education to turn this drug into a success. Can you imagine the amount of time that has gone into developing this drug? ADCETRIS has a unique delivery system that produces progressive effects for fighting cancer. This drug will eradicate cancer cells by attaching itself to the cancerous cell. One of its best attributes of this drug is that it won’t make the patient sick. It would be very hard trying to find another cancer-fighting drug that can duplicate these results.
On the other hand, Seattle Genetics flourished in cancer research. The Washington-based company has been in existence since 1998, but things weren’t too great in the beginning. It turned out that Seattle Genetics was spending more than it was actually earning. This problem caused Dr. Siegall to go back to the drawing board. He, and his small team of associates incorporated a dynamic sales team to get the business back on the right path. This dynamic sales team knew the business from the inside out, and it possessed a strong background in biotech studies. Before too long, Seattle Genetics had started to close on many seven-figure deals and the rest was history. “Our dynamic sales team is the face of the company because these individuals played a key role in its success,” said Siegall.
Bigger and better things are certainly in the works for Seattle Genetics. The company also has an enterprise value of over $9.5 billion. The future of Seattle Genetics and the future of saving lives finally has some sustainability, and that sustainability is Dr. Clay Siegall.